biotech
biotech Articles
Cytokinetics, Inc. (NASDAQ: CYTK) saw its shares take a massive step back in Tuesday’s session after the firm reported negative results for its trial in amyotrophic lateral sclerosis (ALS)....
Published:
Last Updated:
Summit Therapeutics PLC (NASDAQ: SMMT) saw its shares make a handy gain on Monday after the firm announced that it had completed the dosing for the patients in its Duchenne muscular dystrophy (DMD)...
Published:
Last Updated:
Achillion Pharmaceuticals saw its shares make a handy gain on Thursday after the company announced a secondary offering.
Published:
Last Updated:
Acorda Therapeutics saw its shares drop sharply following an announcement that it had paused new enrollment in a long-term safety study. In a sense, Acorda has halted this trial.
Published:
Last Updated:
Loxo Oncology has announced that it will be partnering with Bayer to develop and commercialize larotrectinib and LOXO-195. Investors seem to believe that Loxo would have been better on its own. At...
Published:
Last Updated:
Gilead Sciences, Inc. (NASDAQ: GILD) saw its shares take a step back on Monday after an independent research firm downgraded the stock. Many investors have been hoping that the shares will pull out...
Published:
Last Updated:
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Published:
Last Updated:
Sage Therapeutics shares absolutely exploded on Thursday after the firm announced top-line results from its late-stage trial in severe postpartum depression.
Published:
Last Updated:
Otonomy reported its most recent quarterly results after the markets closed on Wednesday and gave an update on its late-stage trial in patients with Ménière’s disease.
Published:
Last Updated:
Voyager Therapeutics has seen a decent year for its shares and it seems now is the best time to cash in with a secondary offering.
Published:
Last Updated:
Keryx Biopharmaceuticals shares took a hit on Tuesday after the company announced its third-quarter results and an update from the FDA.
Published:
Last Updated:
Sarepta Therapeutics saw its shares hit a new multiyear high on Friday after the firm announced that it received a key approval from the FDA.
Published:
Last Updated:
Intellia Therapeutics saw its shares take a dip on Thursday after the firm announced the pricing of its secondary offering.
Published:
Last Updated:
Geron is one of the few biopharma winners on Tuesday, with the health care sector in general pushing slightly lower on the day.
Published:
In a decisive move, the Neos Therapeutics board of directors unanimously struck down an acquisition proposal from PDL BioPharma.
Published: